Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod)…

Posted: June 22, 2022 at 2:43 am

Ad hoc announcement pursuant to Art. 53 LR

Here is the original post:
Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod)...

Related Posts